Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 1;28(4):taab026.
doi: 10.1093/jtm/taab026.

What can we learn from COVID-19 vaccine R&D in China? A discussion from a public policy perspective

Yinglian Hu  1 , Simiao Chen  2   3
Affiliations

What can we learn from COVID-19 vaccine R&D in China? A discussion from a public policy perspective

Yinglian Hu et al. J Travel Med. .

Abstract

Given China’s relatively weak innovative and regulatory capacity compared with developed countries, China’s progress on COVID-19 vaccines is especially impressive. We summarize three key lessons from China’s experience with COVID-19 vaccine R&D: (i) set strategic vaccine R&D goals and achieve broad consensus; (ii) strengthen coordination across government agencies and (iii) adopt the state-driven collaborative model.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The organizational structure for COVID-19 vaccine R&D in China. Notes: NIFDC, National Institute for Food and Drug Control; CDE, Center for Drug Evaluation; NIFDC and CDE are directly under the NMPA, which is the regulatory authority responsible for drug approval and clinical trial registration; EUA, emergency use authorization; COVAX, COVID-19 vaccines global access; Sinovac, Sinovac Biotech Ltd—a Chinese biopharmaceutical company; CanSino, CanSino Biologics—a Chinese vaccine company
See this image and copyright information in PMC

References

    1. Zhu F-C, Li Y-H, Guan X-H et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 2020. - PMC - PubMed
    1. Gao Q, Bao L, Mao H et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 2020; 369:77–81. - PMC - PubMed
    1. World Health Organization . The COVID-19 Candidate Vaccine Landscape. 2021. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-cand.... 19 Jan 2021, date last accessed.
    1. Xinhua News . Sinopharm Has Released Interim Data from Phase 3 Trial of COVID-19 Inactivated Vaccine [in Chinese]. 2020. http://www.xinhuanet.com/politics/2020-12/30/c_1126926451.htm 2 Jan 2021, date last accessed.
    1. China National Biotec Group Company (CNBG), Bill & Melinda Gates Foundation (BMGF) . International Strategies of China National Biotech Vaccines for Human Use [in Chinese], 2018.

Publication types

Substances